Due to the role of PARP hyperactivation in the mechanism of action of β-lap, PARP inhibitors have been a central focus in improving the efficacy and reducing the toxicity of β-lap for use in NQO1(+) cancers. This evidence concerns the gene NQO1 and cancer.